Loews Corp’s iShares Biotechnology ETF IBB Stock Holding History

Loews Corp’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-120,000	Closed	-$9.46M	–	205
2014 Q1	$9.46M	Buy	+120,000	New	+$10M	0.05%	45

Other funds holding IBB

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Loews Corp's IBB Position: Q2 2014 in Review

Loews Corp sold out of iShares Biotechnology ETF (IBB) in Q2 2014, closing a stake of 120,000 shares — an estimated $9.46M sold.

Loews Corp first reported a position in IBB in Q1 2014 and held it in 1 quarter. The position peaked at $9.46M in Q1 2014. 307 funds tracked by Wall St. Rank hold IBB as of Q2 2014.

Loews Corp reported no remaining iShares Biotechnology ETF position as of Q2 2014 after selling out during the quarter.
Loews Corp sold 120,000 iShares Biotechnology ETF shares in Q2 2014, an estimated $9.46M.
Loews Corp first reported a position in iShares Biotechnology ETF in Q1 2014 and held it in 1 quarter.
Loews Corp's iShares Biotechnology ETF position peaked at $9.46M in Q1 2014.
307 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2014.

Based on Loews Corp's 13F filing for Q2 2014, filed 13 Aug 2014.